Breaks Categories: News

FridayJun 26, 2026 11:40 am

BioMedNewsBreaks — Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) Featured in NetworkNewsAudio Editorial on DNA Repair Therapies 

This article has been disseminated on behalf of Onco-Innovations Limited and may include paid advertising.  Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) announced its inclusion in a NetworkNewsAudio Audio Press Release highlighting the company's approach to next-generation DNA repair therapies for cancer. The audio feature, titled "Next-Generation DNA Repair Therapies Open New Frontiers in Oncology," accompanies a previously published editorial examining the emerging opportunity for PNKP inhibitors within the expanding DNA Damage Response ("DDR") oncology market. The feature highlights Onco-Innovations' exclusive global rights to a portfolio of PNKP inhibitor technology, including core inhibitor molecules, nanoparticle drug delivery technology and synthetic lethality applications designed to target cancer cells. The company said this combination of molecular, delivery…

Continue Reading

FridayJun 26, 2026 10:05 am

BioMedNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Featured in NetworkNewsAudio Editorial on Multiple Sclerosis

This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising. Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) announced its inclusion in a NetworkNewsAudio Audio Press Release highlighting the company's novel approach to treating multiple sclerosis ("MS"). The audio feature, titled "Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis," accompanies a previously published editorial discussing the growing need for therapies that go beyond symptom management in a global MS therapeutics market projected to reach $38.62 billion by 2030. The feature highlights Quantum BioPharma's lead candidate, Lucid-MS, a patented, first-in-class drug candidate designed…

Continue Reading

ThursdayJun 25, 2026 11:45 am

BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Featured in BioMedWire Editorial on Multiple Sclerosis Treatment 

This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising.  Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) announced that it is featured in a BioMedWire editorial examining the need for new approaches to treating multiple sclerosis ("MS"), a progressive neurological disease affecting more than 2.9 million people worldwide. The editorial, titled "The Quest to Repair What Multiple Sclerosis Takes Away," highlights the limitations of current therapies, which can slow disease progression but cannot stop it completely. The editorial discusses Quantum BioPharma's development of Lucid-MS, a patented, first-in-class drug candidate designed to directly target the myelin sheath damaged by MS. The company said the potential therapy is preparing to advance…

Continue Reading

ThursdayJun 25, 2026 11:11 am

BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Reorganizes to Accelerate Global Commercialization Strategy 

HeartBeam (NASDAQ: BEAT) announced a strategic reorganization aimed at accelerating execution, expanding global market reach and improving capital efficiency as it advances commercialization of its cardiac monitoring technology. Under the new structure, Founder and President Branislav Vajdic, Ph.D., and Executive Chairman Rich Ferrari will lead focused implementation teams designed to streamline decision-making, improve accountability and reduce costs. As part of the transition, former CEO Robert Eno will move into a consulting role. The company said its strategy centers on leveraging its patented 3D ECG platform across multiple healthcare channels while advancing development beyond arrhythmia assessment toward heart attack detection. HeartBeam also plans to expand partnerships with governments, health systems,…

Continue Reading

ThursdayJun 25, 2026 9:20 am

BioMedNewsBreaks – Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) Featured in BioMedWire Editorial on Emerging DNA Repair Inhibitors

This article has been disseminated on behalf of Onco-Innovations Limited and may include paid advertising. Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) announced it is featured in a BioMedWire editorial examining the growing market opportunity for next-generation DNA Damage Response ("DDR") inhibitors. The editorial, titled "Next-Generation DNA Repair Inhibitors Could Capture Billions in Emerging Market," highlights the continued expansion of DDR-targeted therapies beyond PARP inhibitors as the global oncology, diagnostics and precision medicine markets continue to grow. The editorial highlights Onco-Innovations' lead candidate, ONC010™, a nanoparticle-encapsulated PNKP inhibitor designed to target a DNA repair enzyme involved in multiple repair pathways. The…

Continue Reading

WednesdayJun 24, 2026 1:12 pm

BioMedNewsBreaks — Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) Targets Next Generation of DNA Damage Response Cancer Therapies 

This article has been disseminated on behalf of Onco-Innovations Limited and may include paid advertising.  Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) is positioning itself within the expanding DNA Damage Response (“DDR”) oncology market through development of ONC010(TM), a nanoparticle-encapsulated PNKP inhibitor designed to target a DNA repair enzyme involved in multiple DNA repair pathways. According to an BioMedWire editorial, DDR-targeting therapies generated more than $7 billion in global sales in 2025, while the broader oncology, diagnostics and precision medicine markets are projected to approach $750 billion by 2030. The company holds exclusive worldwide rights to a portfolio of PNKP inhibitor technologies, including core compounds, delivery systems and synthetic lethality applications intended to support future development…

Continue Reading

WednesdayJun 24, 2026 9:50 am

BioMedNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Advances Lucid-MS Toward Phase 2 Trials for Multiple Sclerosis

This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising. Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) is advancing Lucid-MS, a patented first-in-class drug candidate designed to directly protect the myelin sheath damaged by multiple sclerosis (“MS”), according to an AINewsWire editorial. Unlike existing MS therapies that primarily target the immune system, Lucid-MS is a nonimmunomodulatory, neuroprotective compound intended to prevent myelin degradation. The company recently filed an Investigational New Drug application with the U.S. Food and Drug Administration and is preparing for a phase 2 clinical trial following successful completion of phase 1 safety…

Continue Reading

WednesdayJun 24, 2026 9:40 am

BioMedNewsBreaks – Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO) Expands Coverage of Precision Cardiovascular Tests Through Atlas Healthcare Physicians

Cardio Diagnostics Holdings (NASDAQ: CDIO), an AI-powered precision cardiovascular medicine company, announced that Atlas Healthcare Physicians, an independent physician association serving managed care populations across Los Angeles and Orange counties, will provide coverage for the company’s Epi+Gen CHD(TM) and PrecisionCHD(TM) tests for eligible members with prior authorization. The coverage expands access to physician-ordered blood tests designed to assess coronary heart disease risk and support diagnosis and personalized treatment planning. Cardio Diagnostics said Epi+Gen CHD(TM) evaluates a patient’s three-year risk of a coronary heart disease event, while PrecisionCHD(TM) helps diagnose coronary heart disease and identify its underlying molecular drivers. The company…

Continue Reading

WednesdayJun 24, 2026 9:20 am

BioMedNewsBreaks – Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) Engages Nanosoft to Advance ONC010 Development Program

This article has been disseminated on behalf of Onco-Innovations Limited and may include paid advertising. Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) announced a services agreement with Nanosoft Polymers to support development of ONC010, the company’s lead nanoparticle-formulated PNKP inhibitor. Under the agreement, Nanosoft will provide polymer process development, analytical characterization, formulation optimization, scale-up support and technology transfer services for Onco’s proprietary PEO-PBCL polymer platform as the program advances through IND-enabling development and preparation for future clinical studies. The collaboration is intended to strengthen the manufacturing and formulation foundation of ONC010 by establishing scalable polymer production processes, enhancing analytical methods and…

Continue Reading

WednesdayJun 24, 2026 9:00 am

BioMedNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Expands Heidelberg R&D Facilities To Support Drug Development Pipeline

VERAXA Biotech (NASDAQ: VRXA) an emerging developer of novel cancer therapies, announced it has expanded its laboratory footprint at its existing research and development site in Heidelberg, Germany, under a previously executed long-term lease agreement. The additional space will support planned growth of the company’s R&D team, installation of new laboratory equipment and completion of infrastructure needed to advance future development activities. VERAXA said the expansion aligns with efforts to advance its growing portfolio of proprietary and partnered oncology programs from discovery-stage research toward early clinical development. The company’s pipeline is centered on its BiTAC platform, including BiTAC-TCE and BiTAC-ADC…

Continue Reading